Search results: (10000)
News What Did the Patent for the Synthesis of Highly Purified Trazodone Bring?
Trazodone is a modern antidepressant that is used in the treatment of various types of depression, including those accompanied by anxiety, sleep disorders, or sexual dysfunction. Angelini's invention, with patent protection valid until 2028, presents several methods for the preparation of purified trazodone, or trazodone hydrochloride, which guarantees high purity of this substance and a low content of unwanted residues.
News Effect of Telmisartan and Losartan on Bone Turnover Markers in Patients with Newly Diagnosed Stage I Hypertension
Telmisartan, an AT1 receptor blocker for angiotensin II and partial agonist of the PPAR-γ receptor, is a widely used antihypertensive. The PPAR-γ receptor plays a role in the genesis of osteoblasts and osteoclasts, and antidiabetic drugs from the thiazolidinedione group, which act as agonists of this receptor, have a known inhibitory effect on bone metabolism and increase the risk of non-traumatic fractures. Knowledge regarding the potential similar effects of telmisartan is limited. The following study compared the effects of telmisartan and losartan (an AT1 blocker without agonistic effect on PPAR-γ) on bone turnover markers in patients with newly diagnosed hypertension.
News Lurasidone in Antipsychotic Therapy – A Case Study of a Virtual Patient from the Laurie Project
MUDr. Elis Bartečků, Ph.D., from the Department of Psychiatry at MU LF and FN Brno presented the current possibilities of telemedical education at the XIV congress of the Psychiatric Society of the CLS JEP in Mikulov, specifically the so-called virtual patient within the interactive online Laurie project by Angelini Pharma. The presentation involved the case of a 20-year-old man with a severe psychotic disorder and equally severe somatic comorbidity.
News Another Positive Effect of Diosmin − Influence on Oxidative Stress
Diosmin is an established drug in the therapy of chronic venous insufficiency. It is known to act through several different mechanisms. A study by Polish authors provides evidence of its ability to reduce oxidative stress.
News How to vaccinate children against pneumococcus?
Pneumococcus is a dreaded pathogen causing serious diseases in pediatric patients. However, it can be effectively prevented with commonly available vaccines. Let's look at the updated recommendation of the Czech Vaccinological Society ČLS JEP from April this year.
News Targeted Therapy for DLBCL Patients Who Cannot Undergo Bone Marrow Transplant
An international team of hemato-oncologists has been involved in testing polatuzumab vedotin in patients with diffuse large B-cell lymphoma (DLBCL) who have an unfavorable prognosis. In an article published at the beginning of 2020 in the Journal of Clinical Oncology, they analyze data collected in the early phases of clinical evaluation.
News Long-Term Effect of Nuclear Magnetic Resonance Therapy on Osteoarthritis – An Unconventional Case Report
Osteoarthritis is among the most common health issues in adults, with its prevalence increasing with advancing age. There is currently no causal therapy for the disease; hence, the standard approach is symptomatic treatment with surgical joint reconstruction in advanced stages of the disease. The presented case report describes a successful case of long-term therapy for osteoarthritis using molecular biophysical stimulation.
News Diosmin Succeeded in Preventing Ovarian Hyperstimulation Syndrome in Study
In a recently published study, diosmin was evaluated in women undergoing in vitro fertilization (IVF). Attention was focused on its effect in preventing and treating ovarian hyperstimulation syndrome (OHSS).
News What Can We Expect from Sorafenib in the Treatment of Liver Cancer Affected by Nonalcoholic Fatty Liver Disease?
Ubiquitous and increasingly common obesity is a risk factor for many cancers. Over the past 20 years, studies have linked obesity to higher incidences of breast and colorectal cancers, as well as hepatocellular carcinoma (HCC) associated with nonalcoholic fatty liver disease (NAFLD). What is the efficacy and safety of sorafenib in this patient population, and does it differ from patients with liver cancers caused by viral infection or alcohol abuse? This intrigued a team of researchers from Melbourne, Australia.
News Early Effect of Once-a-Day Trazodone in the Treatment of Major Depressive Disorder
Most antidepressants have a delayed onset of action, reaching therapeutically effective levels only several weeks after the start of treatment. Trazodone is characterized by a specific mechanism of action and a rapid onset of therapeutic effect. A newly published analysis evaluated the available clinical data regarding the early effect of once-a-day trazodone in patients with Major Depressive Disorder (MDD).
News Incidence of CV Events, Malignancies, and Venous Thromboembolism in Patients with RA According to Baseline CV Risk and Administered Treatment
An international team of experts evaluated the impact of cardiovascular (CV) risk on the incidence and risk of major CV events, malignancies, and venous thromboembolism (VTE) in patients with rheumatoid arthritis (RA) treated with tofacitinib compared to tumor necrosis factor (TNF) inhibitors, depending on the level of CV risk at the initiation of this therapy. The authors used data from the ORAL Surveillance study.
News Nearly 20 Years with Bevacizumab Has Brought Hope for Patients and Deeper Understanding of Solid Tumors
Bevacizumab is among the first targeted therapies used in oncology. For many indications where chemotherapy options had been exhausted and few other treatment modalities were available, it changed the treatment approach and brought patients prolonged progression-free survival or even overall survival. It has become a standard of care for many advanced cancers. What do we know today about this monoclonal antibody, first introduced in routine practice in 2005?
News Administration of RAAS Inhibitors in Czech Patients with Heart Failure in Real Practice
A partial analysis of data from the national register of reimbursed health care focused on the epidemiology of heart failure in the Czech Republic showed how inhibitors of the renin-angiotensin-aldosterone system (RAAS), i.e., angiotensin-converting enzyme inhibitors (ACEi), AT1 receptor blockers for angiotensin II (ARBs, sartans), and angiotensin receptor and neprilysin inhibitors (ARNI), were used in real practice in the years 2012–2018 in patients with this disease.
News Impact of Chronic Urticaria on Patients' Quality of Life and Society
An international team of dermatologists has mapped out the impact of chronic urticaria on various aspects of patients' lives and the economic burden this long-term disease, without available causal treatment, represents for society, according to available literature.
News Induction vs. Escalation Treatment: Which Strategy to Choose in the Therapy of Multiple Sclerosis?
Opinions on the optimal therapy for multiple sclerosis (MS) are constantly evolving, and experts are debating the most appropriate first-line treatment strategy. A British cohort study focused on the long-term outcomes of induction and escalation therapies, two key approaches in the treatment of MS.
News Population Pharmacokinetic Model in Patients with von Willebrand Disease
Dutch authors presented a potential population pharmacokinetic model describing levels of von Willebrand factor and coagulation factor VIII during and after surgical procedures in patients with von Willebrand disease.
News How Does the Long-Term Effect of Beta Blocker Use Affect Clinical Outcomes in Patients After Myocardial Infarction?
In patients after myocardial infarction (MI), beta blockers (BB) still hold an important place in secondary prevention according to recommended procedures. However, the question could be their long-term effect on clinical outcomes, as different results can be found in the literature – this fact led the authors of the work cited below to perform a systematic review and meta-analysis of studies dedicated to this issue.
News Incidence of Secondary Malignancies in CLL Patients on FCR Regimen in Central Europe
Chronic lymphocytic leukemia (CLL) represents the most common type of leukemia in Western countries with closely related incidence in Central European states. Since 2000, new therapeutic regimens have been explored and applied in an effort to improve patient prognosis, including the combination of fludarabine, cyclophosphamide, and rituximab (FCR). However, the development of new therapeutic regimens is also associated with concerns about the risk of secondary malignancies.
News Mass in the Left Atrium Appendage - Case Report
A symptomatic mass in the left atrial appendage warrants thorough investigation and radical treatment – unless it is in the heart of a polymorbid patient, as was the case in the following report.
News Impact of Body Mass Index on Survival and Treatment Outcomes of Metastatic Colorectal Cancer
A pooled analysis of 25 studies with patients in the first line of treatment for metastatic colorectal cancer (mCRC) evaluated the prognostic and predictive significance of body mass index (BMI). Until its publication in 2015, only the adverse impact of low and high BMI on outcomes in patients with early stages of colorectal cancer was known.
News Idiopathic Pulmonary Fibrosis: What Can a General Practitioner Do?
When a previously healthy patient becomes breathless, it's never good news. Among the particularly serious issues that breathlessness can signal is idiopathic pulmonary fibrosis (IPF). However, its prognosis no longer has to be as unfavorable as before, especially if diagnosed early.
News 6 Possible Benefits of Adding Empagliflozin to Metformin
Currently, there is intense discussion about the advantages of sodium-glucose co-transporter 2 inhibitors (SGLT2i, also known as gliflozins) in terms of their cardio and nephroprotective properties. Below, we summarize the proven beneficial effects specifically associated with adding empagliflozin to metformin and mention the indications for empagliflozin, which are reimbursed.
News INFOGRAPHIC: Determining the Target Intraocular Pressure in Glaucoma Therapy
The goal of glaucoma treatment is to preserve the visual field and the quality of life of patients. Currently, the only approach to preserving the visual field of patients is to reduce intraocular pressure (IOP). Its target value should be determined for each patient with consideration of individual risk factors. The following comprehensive infographic shows which factors should be considered according to the current recommendations of the European Glaucoma Society (EGS).